Display options
Cite
Napolitano A, Miller S, Murgatroyd PR, et al. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J Clin Transl Endocrinol. 2013;1(1):e3-e8doi: 10.1016/j.jcte.2013.12.001.
Napolitano, A., Miller, S., Murgatroyd, P. R., Hussey, E., Dobbins, R. L., Bullmore, E. T., & Nunez, D. J. R. (2014). Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. Journal of clinical & translational endocrinology, 1(1), e3-e8. https://doi.org/10.1016/j.jcte.2013.12.001
Napolitano, Antonella, et al. "Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects." Journal of clinical & translational endocrinology vol. 1,1 (2014): e3-e8. doi: https://doi.org/10.1016/j.jcte.2013.12.001
Napolitano A, Miller S, Murgatroyd PR, Hussey E, Dobbins RL, Bullmore ET, Nunez DJR. Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J Clin Transl Endocrinol. 2013 Dec 11;1(1):e3-e8. doi: 10.1016/j.jcte.2013.12.001. eCollection 2014 Mar. PMID: 29235586; PMCID: PMC5685025.
Copy Download .nbib Format: NLM
Share it on

J Clin Transl Endocrinol. 2013 Dec 11;1(1):e3-e8. doi: 10.1016/j.jcte.2013.12.001. eCollection 2014 Mar.

Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.

Journal of clinical & translational endocrinology

Antonella Napolitano, Sam Miller, Peter R Murgatroyd, Elizabeth Hussey, Robert L Dobbins, Edward T Bullmore, Derek J R Nunez

Affiliations

  1. Clinical Unit in Cambridge, GlaxoSmithKline, Addenbrookes Hospital, Cambridge, UK.
  2. Wellcome Trust Clinical Research Facility, Cambridge University Hospital NHS Trust, UK.
  3. Metabolic Pathways and Cardiovascular Unit, GlaxoSmithKline, NC, USA.

PMID: 29235586 PMCID: PMC5685025 DOI: 10.1016/j.jcte.2013.12.001

Abstract

Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2) increase glucose excretion in the urine and improve blood glucose in Type 2 diabetes mellitus. Glycosuria provides an energy and osmotic drain that could alter body composition. We therefore conducted a pilot study comparing the effects on body composition of two SGLT2 inhibitors, remogliflozin etabonate (RE) 250 mg TID (

Keywords: Experimental medicine; Glycosuria; Obesity; SGTL-2 inhibitors

References

  1. Obesity (Silver Spring). 2010 Feb;18(2):391-6 - PubMed
  2. Int J Clin Pract Suppl. 2007 Dec;(157):47-57 - PubMed
  3. Diabetes Care. 2012 Jun;35(6):1364-79 - PubMed
  4. Diabetes Res Clin Pract. 2010 Jan;87(1):4-14 - PubMed
  5. J Pharmacol Exp Ther. 2008 Oct;327(1):268-76 - PubMed
  6. J Clin Pharmacol. 2010 Jun;50(6):636-46 - PubMed
  7. Am J Physiol. 1992 Sep;263(3 Pt 2):F459-65 - PubMed
  8. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31 - PubMed
  9. J Pharmacol Exp Ther. 2007 Jan;320(1):323-30 - PubMed
  10. J Clin Endocrinol Metab. 2006 Aug;91(8):3219-23 - PubMed
  11. Diabetes. 2008 Jun;57(6):1723-9 - PubMed
  12. Diabetologia. 2009 Nov;52(11):2345-2349 - PubMed
  13. Clin Sci (Lond). 1992 Jun;82(6):687-93 - PubMed
  14. Diabetes Obes Metab. 2012 Jan;14(1):15-22 - PubMed
  15. Am J Clin Nutr. 1982 Mar;35(3):591-4 - PubMed
  16. Obesity (Silver Spring). 2008 Jan;16(1):191-8 - PubMed
  17. World Health Organ Tech Rep Ser. 1985;724:1-206 - PubMed

Publication Types